MI Technologies Inc. (“FMI”) has developed an ultra high resolution diagnostic imaging technology that can be combined with drugs and molecular tracers for early detection and monitoring of neurodegenerative disorders. FMI’s PET/CT/SPECT system offers a superior and more cost-effective solution that enables advanced therapy and possible cures for Alzheimer’s disease, Vascular Dementia, Parkinson’s disease and other dementias. In addition, its unique Fused Multimodality Imaging will offer the data critical to earlier physician diagnosis of stroke, and head and neck cancers than are possible with current technology. FMI’s mantra is “Drugs need Imaging and Imaging needs Drugs” for early asymptomatic diagnostics and personalized medicine.
PET/CT/SPECT images are combined, or “fused,” to provide information as to the sensitivity and specificity for the type of cancer present, three dimensional information as to the physical location of the cancer and reference information for doctors to plan stereo-tactic biopsy, minimally invasive surgery and image guided therapy.